Norman Scherzer

FDA approves Stivarga for advanced GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.

By |2019-09-20T13:00:30-04:00February 25th, 2013|Clinical Trials, Drug Treatment, News, Stivarga|

LRG closes out 2012 in the spotlight: advocacy, support & research highlighted

The Life Raft Group is dedicated to the welfare and survival of GIST patients worldwide and we carry out our mission through research, patient support & education and advocacy. The LRG was highlighted in all three areas at the end of 2012 and we wanted to share the important work we’re doing with all of you.

By |2019-09-20T13:12:51-04:00February 1st, 2013|Advocacy, News|

Norman Scherzer Discusses the Founding of the Life Raft Group and the Importance of Gleevec

Executive Director Norman Scherzer talks about the founding of the Life Raft Group and the importance of Gleevec in the fight against GIST (Gastrointestinal Stromal Tumor).

By |2018-08-06T10:51:52-04:00May 31st, 2012|Video|
Go to Top